Biotech Firm to Study Rosehips Unique to Canada
Biotechnology firm Ceapro Inc. (Edmonton, AB, Canada) has signed a material transfer agreement (MTA) with the National Research Council of Canada (NRC) to study the active ingredients in a species of rosehips the company says is unique to Canada’s Prince Edward Island.
Biotechnology firm Ceapro Inc. (Edmonton, AB, Canada) has signed a material transfer agreement (MTA) with the National Research Council of Canada (NRC) to study the active ingredients in a species of rosehips the company says is unique to Canada’s Prince Edward Island.
“Previous extensive collaborative work by the University of Prince Edward Island, NRC, and Agriculture and Agri-Food Canada found that a specific variety contained multiple compounds capable of providing therapeutic benefits,” Ceapro said. The entities will study the effects of combining the active ingredients of the rosehips with Ceapro’s active ingredients.
“The variety is unique, and this provides a degree of protection from competitors,” said David Fielder, Ceapro’s chief science officer. The company has the option to commercialize some of the intellectual property that results from the studies. “This project exemplifies everything we would like to see in a new commercialization project,” Fielder added.
Prince Edward Island has also awarded the project a grant of up to $100,000.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
